<DOC>
	<DOC>NCT00851318</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-001.</brief_summary>
	<brief_title>Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients</brief_title>
	<detailed_description>This study was initiated by Otsuka Pharmaceutical Co., Ltd and transferred to Astellas on 12/04/2012.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects who participated in Study 27508001 and meet all of the criteria described below. Patients who did not reach ACR20, and prematurely discontinued Study 27508001 at Week 16 or completed Study 27508001 by Week 24. Patients who are able to receive treatment with MTX, by Week 52. Patients who experienced an important protocol deviation as mentioned below during Study 27508001. Patients who received live or attenuated vaccines during Study 27508001(Except for influenza or pneumococcal vaccines). Patients who were found to have tuberculosis on a chest Xray during Study 27508001. Patients who required treatment for the same infection at two or more different times during Study 27508001 Women who are pregnant, are lactating, of childbearing potential and wish to conceive during the study and poststudy 3 months. Patients whom the investigator has decided to be inappropriate for participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>